Cochrane · systematic review · CD007076
Pregabalin for neuropathic pain in adults
Derry, S, Bell, RF, Straube, S, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
33
current version
GRADE rated
31
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 6.1%Very low 1 · 3%Low 2 · 6.1%Moderate 18 · 54.5%High 10 · 30.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Pregabalin 300 mg compared with placebo for postherpetic neuralgia
Population: adults with moderate or severe pain associated with postherpetic neuralgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 30% pain intensity reduction Pregabalin 300 mg vs placebo | no estimate extracted | 3 studies · 589 participants | Moderate |
At least 50% pain intensity reduction Pregabalin 300 mg vs placebo | no estimate extracted | 4 studies · 713 participants | Moderate |
Patient Global Impression of Change ‐ much or very much improved Pregabalin 300 mg vs placebo | no estimate extracted | 3 studies · 568 participants | Low |
Lack of efficacy withdrawal Pregabalin 300 mg vs placebo | no estimate extracted | 5 studies · 933 participants | High |
Somnolence Pregabalin 300 mg vs placebo | no estimate extracted | 5 studies · 933 participants | Moderate |
Dizziness Pregabalin 300 mg vs placebo | no estimate extracted | 5 studies · 933 participants | Moderate |
Adverse event withdrawal Pregabalin 300 mg vs placebo | no estimate extracted | 5 studies · 933 participants | High |
Pregabalin 600 mg compared with placebo for postherpetic neuralgia
Population: adults with moderate or severe pain associated with postherpetic neuralgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 30% pain intensity reduction Pregabalin 600 mg vs placebo | no estimate extracted | 3 studies · 537 participants | Moderate |
At least 50% pain intensity reduction Pregabalin 600 mg vs placebo | no estimate extracted | 4 studies · 732 participants | Moderate |
Patient Global Impression of Change ‐ much or very much improved Pregabalin 600 mg vs placebo | no estimate extracted | NR | Very low |
Lack of efficacy withdrawal Pregabalin 600 mg vs placebo | no estimate extracted | 4 studies · 732 participants | High |
Somnolence Pregabalin 600 mg vs placebo | no estimate extracted | 4 studies · 732 participants | Moderate |
Dizziness Pregabalin 600 mg vs placebo | no estimate extracted | 4 studies · 732 participants | Moderate |
Adverse event withdrawal Pregabalin 600 mg vs placebo | no estimate extracted | 4 studies · 732 participants | High |
Pregabalin 300 mg compared with placebo for painful diabetic neuropathy
Population: adults with moderate or severe pain associated with painful diabetic neuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 30% pain intensity reduction Pregabalin 300 mg vs placebo | no estimate extracted | 8 studies · 2320 participants | Moderate |
At least 50% pain intensity reduction Pregabalin 300 mg vs placebo | no estimate extracted | 11 studies · 2931 participants | Moderate |
Patient Global Impression of Change ‐ much or very much improved Pregabalin 300 mg vs placebo | no estimate extracted | 5 studies · 1050 participants | Moderate |
Patient Global Impression of Change ‐ very much improved Pregabalin 300 mg vs placebo | no estimate extracted | 2 studies · 501 participants | Low |
Lack of efficacy withdrawal Pregabalin 300 mg vs placebo | no estimate extracted | 10 studies · 2430 participants | High |
Somnolence Pregabalin 300 mg vs placebo | no estimate extracted | 12 studies · 3315 participants | Moderate |
Dizziness Pregabalin 300 mg vs placebo | no estimate extracted | 12 studies · 3315 participants | Moderate |
Adverse event withdrawal Pregabalin 300 mg vs placebo | no estimate extracted | 13 studies · 3384 participants | High |
Pregabalin 600 mg compared with placebo for painful diabetic neuropathy
Population: adults with moderate or severe pain associated with painful diabetic neuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 30% pain intensity reduction Pregabalin 600 mg vs placebo | no estimate extracted | 3 studies · 789 participants | Moderate |
At least 50% pain intensity reduction Pregabalin 600 mg vs placebo | no estimate extracted | 7 studies · 1360 participants | Moderate |
Patient Global Impression of Change ‐ much or very much improved Pregabalin 600 mg vs placebo | no estimate extracted | 3 studies · 537 participants | Moderate |
Lack of efficacy withdrawal Pregabalin 600 mg vs placebo | no estimate extracted | 5 studies · 879 participants | High |
Somnolence Pregabalin 600 mg vs placebo | no estimate extracted | 7 studies · 1501 participants | Moderate |
Dizziness Pregabalin 600 mg vs placebo | no estimate extracted | 8 studies · 1885 participants | Moderate |
Adverse event withdrawal Pregabalin 600 mg vs placebo | no estimate extracted | 8 studies · 1669 participants | High |
Pregabalin 300 mg or 600 mg compared with placebo for any neuropathic pain: any adverse event and serious adverse events
Population: adults with moderate or severe neuropathic pain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
mg pregabalin Pregabalin 300 mg or 600 mg vs placebo | no estimate extracted | 300 participants | Ungraded |
At least 1 AE Pregabalin 300 mg or 600 mg vs placebo | no estimate extracted | 15 studies · 3697 participants | High |
Serious AE Pregabalin 300 mg or 600 mg vs placebo | no estimate extracted | 17 studies · 4112 participants | High |
mg pregabalin Pregabalin 300 mg or 600 mg vs placebo | no estimate extracted | 600 participants | Ungraded |